Safety and immunogenicity of whole virion influenza vaccines.
- Conditions
- influenza (griep)
- Registration Number
- NL-OMON22232
- Lead Sponsor
- RIVM, Bilthoven
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 150
Inclusion Criteria
1. Age 18 to 49 years;
2. If female: Willing to use contraceptive measures during the study;
Exclusion Criteria
1. Having had an infectious disease with fever (including influenza) within the last 14 days;
2. Present evidence of serious disease(s) demanding medical treatment that might interfere with the results of the study such as diseases which interfere with the immune system;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of systemic and local adverse events.
- Secondary Outcome Measures
Name Time Method Anti-hemagglutinin antibody against the influenza vaccine strain by HI test.